Completed PHASE2 INTERVENTIONAL 1-arm NCT00631202

Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia

Single-Center, Open-Label, Sequential Trial to Test the Efficacy, Safety and Tolerability of Epoetin Alfa in Patients With Friedreich's Ataxia

Sponsor: Federico II University

Conditions Friedreich's Ataxia

Interventions Epoetin alfa

Updated 5 times since 2017 Last updated: May 26, 2010 Started: Feb 29, 2008 Primary completion: Dec 31, 2008 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00631202, this PHASE2 trial focuses on Friedreich's Ataxia and remains completed. Sponsored by Federico II University, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Federico II University

Data source: Federico II University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Naples, Italy